Showing 3411-3420 of 6631 results for "".
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://practicaldermatology.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- Stigmatization Based on Skin Disorders Linked with Diminished Life Quality in Pediatric Patientshttps://practicaldermatology.com/news/stigmatization-based-skin-disorders-linked-diminished-life-quality-pediatric-patients/2467151/New research suggests that skin disorder-based stigmatization is perhaps unsurprisingly associated with a diminished quality of life and poorer mental health. Researchers conducted a cross-sectional, single-visit study that included 1,671 children (57.9% female) across 32 pediatric center
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- Link Between UV Exposure and Cutaneous Angiosarcoma Incidencehttps://practicaldermatology.com/news/link-between-uv-exposure-and-cutaneous-angiosarcoma-incidence/2467139/Ambient ultraviolet radiation (UVR) was associated with a higher incidence of cutaneous angiosarcoma (cAS), an aggressive lymphatic/vascular endothelial-based cancer. Researchers publishing the findings in a research letter in Journal of the American Academy of Dermatology (JAAD)<
- New siRNA Therapy for Benign Lesions Could Reduce Risk for Future Cancerhttps://practicaldermatology.com/news/new-sirna-therapy-benign-lesions-precursor-cancer/2467089/Researchers have developed a novel genetic therapy for reversing the formation of giant moles in patients with congenital melanocytic naevus syndrome (CMN), thereby also reducing their risk for developing melanoma later on. The therapy for this rare condition works by suppressing the NRAS
- PD-1 Gene Variants Linked to Melanoma Riskhttps://practicaldermatology.com/news/pd-1-gene-variants-linked-melanoma-risk/2467088/A recent study has highlighted significant associations between specific single nucleotide variants (SNVs) in the PD-1 and PD-L1 genes and the risk of metastatic melanoma (MM). Researchers conducted the study at IRCCS Ospedale Policlinico San Martino in Genova, Italy, and included 125 patients wi
- Olympian Suni Lee Speaks on AD Panelhttps://practicaldermatology.com/news/olympian-suni-lee-speaks-ad-panel/2467107/Gymnast Suni Lee plans to defend her Olympic gold medal this summer in Paris, but first, she took time to participate in a panel discussion on a topic that has plagued her for several years: atopic dermatitis, or eczema. The 21-year-old American joined National Eczema Association President
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro